10 Results for "

her2-expressing tumors

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "her2-expressing tumors" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-164992
Synonyms: MRG002; Trastuzumab MMAE
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-156035
CAS No.: 102650-30-6
Purity:  96.05%
Target:  

Drug Intermediate

Research Areas:  

Others

Bz‑DTPA is a bifunctional chelator that can conjugate indium radionuclides to targeting proteins for tumor-targeted tracing. Bz‑DTPA is mainly used in studies related to radioactive targeting molecules .
loading...
    loading...
Cat. No.: HY-W614269
CAS No.: 306776-79-4
Research Areas:  

Cancer

DOTA-GA(tBu)4 stabilizes the attachment of radiometals to ligands. DOTA-GA(tBu)4 improves the biodistribution of radiolabeled second-generation Affibody molecules by increasing their net negative charge and reducing hepatic uptake, leading to enhanced tumor-to-blood and tumor-to-liver ratios. DOTA-GA(tBu)4 targets HER2>-expressing breast and gastrointestinal cancer .
loading...
    loading...
Cat. No.: HY-P99896
CAS No.: 2361325-98-4
Synonyms: BTRC-4017A; RG-6194

Target:  

EGFR CD3

Research Areas:  

Cancer

Runimotamab (BTRC-4017A) is a HER2 and CD3 T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-164919
CAS No.: 2847102-44-5
Synonyms: XMT-2056
Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate (ADC) targeting HER2, linked to a payload composed of XMT-1519 conjugate-1 (HY-148067) and STING agonist-20 (HY-148068). Calotatug ginistinag activates the STING signaling pathway in tumor cells and tumor-resident immune cells, induces the production of type I interferons and cytokines (CXCL10, IFN-β, IL-6, TNF-α, triggers innate anti-tumor immune responses, and exerts a bystander effect. Calotatug ginistinag exhibits efficacy against HER2-expressing cancer cells in co-culture with PBMCs. Calotatug ginistinag induces tumor regression and reduces systemic inflammation in various tumor models. Combination treatment with Calotatug ginistinag, Trastuzumab (HY-P9907) and T-DXd (HY-138298) yields benefits. Calotatug ginistinag can be used in studies related to HER2-expressing solid tumors such as breast cancer, gastric cancer and ovarian cancer .
loading...
    loading...
Cat. No.: HY-P9994
CAS No.: 2500674-05-3
Synonyms: SBT6050
Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .
loading...
    loading...
Cat. No.: HY-P12120
CAS No.: 499773-67-0
Synonyms: KCCYSL
Research Areas:  

Cancer

ErbB-2-binding peptide-2 (KCCYSL) is a peptide targeting ErbB-2/HER2, which specifically binds to the extracellular domain of HER2 and accumulates in HER2-expressing cancer cells. When radiolabeled, ErbB-2-binding peptide-2 serves as a SPECT/CT and PET imaging agent, enabling the visualization of HER2-expressing tumor xenografts. ErbB-2-binding peptide-2 is applicable to research related to ovarian cancer and breast cancer .
loading...
    loading...
Cat. No.: HY-W540123
CAS No.: 186046-82-2
Research Areas:  

Cancer

Fmoc-PNA-A(Bhoc)-OH is a protected peptide nucleic acid (PNA) monomer carrying an adenine base. Fmoc-PNA-A(Bhoc)-OH contains Fmoc and benzhydryloxycarbonyl (Bhoc) protecting groups, and serves as a standard building block designed specifically for solid-phase PNA synthesis. Fmoc-PNA-A(Bhoc)-OH can be efficiently used to synthesize PNA-based sequence-specific hybridization probes. These probes have broad applications in molecular biology research; for example, they can be used in HER2-expressing tumor-related studies, providing tools for disease diagnosis and mechanism exploration .
loading...
    loading...
Cat. No.: HY-W717782
CAS No.: 2614335-77-0
Target:  

Drug Intermediate

Research Areas:  

Others

Bz-DTPA hydrochloride is a bifunctional chelator that can conjugate indium radionuclides to targeting proteins for tumor-targeted tracing. Bz-DTPA hydrochloride is mainly used in studies related to radioactive targeting molecules .
loading...
    loading...
Cat. No.: HY-183253
DL149 is a component of an antibody-drug conjugate (ADC) formed by conjugating the eIF4A inhibitor FD236 (HY-186186) with an ADC linker, and exhibits potential antitumor activity. DL149 can bind to an anti-HER2 antibody to form a complete ADC molecule, which precisely binds to the HER2 receptor on the surface of tumor cells. After internalization into cells, it releases the eIF4A inhibitor payload. DL149 irreversibly blocks the mRNA translation process in tumor cells, thereby inhibiting tumor cell proliferation and inducing their death. DL149 exhibits in vivo antitumor activity in the SK-OV-3 xenograft tumor model, and can be used for the research of HER2-positive solid tumors .
loading...
    loading...